{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:57Z","timestamp":1792787817639,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Natural Science Foundation of China","award":["81402120"],"award-info":[{"award-number":["81402120"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the National Natural Science Foundation of China","award":["82504290"],"award-info":[{"award-number":["82504290"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"China Postdoctoral Science Foundation","award":["GZC20242035"],"award-info":[{"award-number":["GZC20242035"]}],"id":[{"id":"https:\/\/ror.org\/0426zh255","id-type":"ROR","asserted-by":"crossref"}]},{"name":"China Postdoctoral Science Foundation","award":["BX20250226"],"award-info":[{"award-number":["BX20250226"]}],"id":[{"id":"https:\/\/ror.org\/0426zh255","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Hunan Province","award":["2025JJ60549"],"award-info":[{"award-number":["2025JJ60549"]}]},{"name":"the Natural Science Foundation of Hunan Province","award":["2026JJ60577"],"award-info":[{"award-number":["2026JJ60577"]}]},{"name":"the Health Research Project of Hunan Provincial Health Commission","award":["20257447"],"award-info":[{"award-number":["20257447"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis is a chronic inflammatory skin disease driven by aberrant keratinocyte activation and immune dysregulation. Protein arginine methyltransferase 5 (PRMT5) was identified as a candidate regulator in psoriatic keratinocytes, yet its function and mechanistic role in psoriasis pathogenesis remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed multiple public bulk RNA-sequencing and single-cell RNA-sequencing (scRNA-seq) transcriptomic datasets from psoriasis patients to assess PRMT5 mRNA expression and distribution. Protein expression was further validated by immunofluorescence staining of psoriatic lesion biopsies. Functional validation employed siRNA-mediated\n                      <jats:italic>Prmt5<\/jats:italic>\n                      knockdown in imiquimod-induced psoriasis model. Transcriptomic profiling combined with in vitro human primary keratinocytes experiments was performed with\n                      <jats:italic>PRMT5<\/jats:italic>\n                      knockdown or inhibition to map downstream potential mechanisms. Specific mechanistic investigations included co-immunoprecipitation, molecular docking, GST pull-down, mass spectrometry, and site-directed mutagenesis to characterize the PRMT5-p65 interaction and symmetric dimethylarginine (SDMA) modification. Finally, the therapeutic potential of PRMT5 inhibition by EPZ015666 was evaluated in imiquimod and IL-23-induced psoriasis models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PRMT5 was markedly upregulated in psoriatic keratinocytes. Knockdown of\n                      <jats:italic>Prmt5<\/jats:italic>\n                      reduces local inflammation responses in the imiquimod-induced mouse model. Transcriptomic profiling combined with in vitro detection defined that inhibition of PRMT5 can dampen the inflammatory response of keratinocytes. Mechanistically, PRMT5 inhibition markedly reduces p65 protein levels, prompting further exploration of the PRMT5-p65 axis. Co-immunoprecipitation, molecular docking and GST pull down assay confirmed a direct PRMT5-p65 interaction; PRMT5 knockdown attenuated this interaction, diminishes symmetric dimethylarginine (SDMA) modification of p65, and compromises p65 protein stability. Accordingly, p65 overexpression restored inflammatory cytokine production in PRMT5-knockdown keratinocytes, functionally validating this regulatory axis. Mass spectrometry combined with site-directed mutation experiments revealed that PRMT5 facilitates p65 symmetric dimethylation at R158 and R166, which suppresses autophagy-mediated lysosomal degradation, thereby promoting p65-dependent cytokines expression. Pharmacological inhibition of PRMT5 with EPZ015666 ameliorates psoriatic inflammatory responses in vivo, underscoring its translational potential value.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings establish a PRMT5-p65 regulatory axis wherein PRMT5-mediated symmetric dimethylation at R158 and R166 stabilizes p65 by autophagy-mediated lysosomal degradation and amplifies NF-\u03baB-driven inflammation in keratinocytes, identifying PRMT5 as a potential therapeutic target in psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-026-01558-6","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:25:29Z","timestamp":1783653929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PRMT5 promotes psoriatic inflammation through mediating dimethylation of p65 in keratinocytes"],"prefix":"10.1186","volume":"32","author":[{"given":"Xiaoru","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"1558_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s42003-024-06290-7","volume":"7","author":"Y Abe","year":"2024","unstructured":"Abe Y, Sano T, Otsuka N, Ogawa M, Tanaka N. PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth. Commun Biol. 2024;7:593.","journal-title":"Commun Biol"},{"key":"1558_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218075","volume":"634","author":"F Alipourgivi","year":"2025","unstructured":"Alipourgivi F, Su J, Lu T. Cracking PRMT5: mechanistic insights, clinical advances, and AI-driven strategies. Cancer Lett. 2025;634:218075.","journal-title":"Cancer Lett"},{"key":"1558_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945\u201360.","journal-title":"JAMA"},{"key":"1558_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","volume":"11","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, et al. Psoriasis Nat Rev Dis Primer. 2025;11:45.","journal-title":"Psoriasis Nat Rev Dis Primer"},{"key":"1558_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","volume":"65","author":"RS Blanc","year":"2017","unstructured":"Blanc RS, Richard S. Arginine methylation: the coming of age. Mol Cell. 2017;65:8\u201324.","journal-title":"Mol Cell"},{"key":"1558_CR6","doi-asserted-by":"publisher","first-page":"2003047","DOI":"10.1002\/advs.202003047","volume":"8","author":"C Cai","year":"2021","unstructured":"Cai C, et al. PRMT5 Enables Robust STAT3 Activation via Arginine Symmetric Dimethylation of SMAD7. Adv Sci. 2021;8:2003047.","journal-title":"Adv Sci"},{"key":"1558_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.molmed.2016.03.002","volume":"22","author":"G Cildir","year":"2016","unstructured":"Cildir G, Low KC, Tergaonkar V. Noncanonical NF-\u03baB signaling in health and disease. Trends Mol Med. 2016;22:414\u201329.","journal-title":"Trends Mol Med"},{"key":"1558_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","volume":"9","author":"E Fitch","year":"2007","unstructured":"Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of Psoriasis: Recent Advances on IL-23 and Th17 Cytokines. Curr Rheumatol Rep. 2007;9:461\u20137.","journal-title":"Curr Rheumatol Rep"},{"key":"1558_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2025.168967","volume":"437","author":"J Fleming","year":"2025","unstructured":"Fleming J, et al. AlphaFold protein structure database and 3D-Beacons: new data and capabilities. J Mol Biol. 2025;437:168967.","journal-title":"J Mol Biol"},{"key":"1558_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccell.2019.07.003","volume":"36","author":"JY Fong","year":"2019","unstructured":"Fong JY, et al. Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell. 2019;36:194-209.e9.","journal-title":"Cancer Cell"},{"key":"1558_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","volume":"8","author":"J Guo","year":"2023","unstructured":"Guo J, et al. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8:437.","journal-title":"Signal Transduct Target Ther"},{"key":"1558_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","volume":"69","author":"AM Goldminz","year":"2013","unstructured":"Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF. NF-\u03baB: an essential transcription factor in psoriasis. J Dermatol Sci. 2013;69:89\u201394.","journal-title":"J Dermatol Sci"},{"key":"1558_CR13","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.annonc.2025.08.3757","volume":"36","author":"MM Gounder","year":"2025","unstructured":"Gounder MM, et al. Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers. Ann Oncol. 2025;36:1480\u201391.","journal-title":"Ann Oncol"},{"key":"1558_CR14","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis Lancet. 2021;397:1301\u201315.","journal-title":"Psoriasis Lancet"},{"key":"1558_CR15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41580-019-0155-x","volume":"20","author":"E Guccione","year":"2019","unstructured":"Guccione E, Richard S. The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol. 2019;20:642\u201357.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1558_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148905","volume":"11","author":"DP Harris","year":"2016","unstructured":"Harris DP, Chandrasekharan UM, Bandyopadhyay S, Willard B, DiCorleto PE. PRMT5-mediated methylation of NF-\u03baB p65 at Arg174 is required for endothelial CXCL11 gene induction in response to TNF-\u03b1 and IFN-\u03b3 costimulation. PLoS ONE. 2016;11:e0148905.","journal-title":"PLoS ONE"},{"key":"1558_CR17","doi-asserted-by":"publisher","first-page":"15328","DOI":"10.1074\/jbc.M114.547349","volume":"289","author":"DP Harris","year":"2014","unstructured":"Harris DP, Bandyopadhyay S, Maxwell TJ, Willard B, DiCorleto PE. Tumor necrosis factor (TNF)-\u03b1 induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-\u03baB p65 methylation. J Biol Chem. 2014;289:15328\u201339.","journal-title":"J Biol Chem"},{"key":"1558_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140:645\u201353.","journal-title":"J Allergy Clin Immunol"},{"key":"1558_CR19","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","volume":"351","author":"GV Kryukov","year":"2016","unstructured":"Kryukov GV, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351:1214\u20138.","journal-title":"Science"},{"key":"1558_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10822-010-9395-8","volume":"25","author":"MA Lill","year":"2011","unstructured":"Lill MA, Danielson ML. Computer-aided drug design platform using PyMOL. J Comput Aided Mol des. 2011;25:13\u20139.","journal-title":"J Comput Aided Mol des"},{"key":"1558_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105452","volume":"110","author":"AR Liu","year":"2024","unstructured":"Liu AR, et al. NF-\u03baB c-Rel is a critical regulator of TLR7-induced inflammation in psoriasis. EBioMedicine. 2024;110:105452.","journal-title":"EBioMedicine"},{"key":"1558_CR22","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.7150\/thno.42047","volume":"10","author":"M Liu","year":"2020","unstructured":"Liu M, et al. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression. Theranostics. 2020;10:4437\u201352.","journal-title":"Theranostics"},{"key":"1558_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","volume":"34","author":"MA Lowes","year":"2013","unstructured":"Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34:174\u201381.","journal-title":"Trends Immunol"},{"key":"1558_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","volume":"22","author":"H Mao","year":"2025","unstructured":"Mao H, Zhao X, Sun S. NF-\u03baB in inflammation and cancer. Cell Mol Immunol. 2025;22:811\u201339.","journal-title":"Cell Mol Immunol"},{"key":"1558_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI184283","author":"H Ozturk","year":"2025","unstructured":"Ozturk H, et al. High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/JCI184283.","journal-title":"J Clin Invest"},{"key":"1558_CR26","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.1038\/sj.onc.1209937","volume":"25","author":"ND Perkins","year":"2006","unstructured":"Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene. 2006;25:6717\u201330.","journal-title":"Oncogene"},{"key":"1558_CR27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.gendis.2022.04.001","volume":"10","author":"L Prabhu","year":"2022","unstructured":"Prabhu L, et al. Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue. Genes Dis. 2022;10:267\u201383.","journal-title":"Genes Dis"},{"key":"1558_CR28","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","volume":"35","author":"J Rodon","year":"2024","unstructured":"Rodon J, et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann Oncol. 2024;35:1138\u201347.","journal-title":"Ann Oncol"},{"key":"1558_CR29","doi-asserted-by":"publisher","first-page":"W463","DOI":"10.1093\/nar\/gkaf361","volume":"53","author":"P Schake","year":"2025","unstructured":"Schake P, Bolz SN, Linnemann K, Schroeder M. PLIP 2025: introducing protein-protein interactions to the protein-ligand interaction profiler. Nucleic Acids Res. 2025;53:W463\u20135.","journal-title":"Nucleic Acids Res"},{"key":"1558_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-0716-3441-7_5","volume":"2714","author":"A Singh","year":"2024","unstructured":"Singh A, Copeland MM, Kundrotas PJ, Vakser IA. GRAMM Web Server for Protein Docking. Methods Mol Biol. 2024;2714:101\u201312.","journal-title":"Methods Mol Biol"},{"key":"1558_CR31","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","volume":"72","author":"N Stopa","year":"2015","unstructured":"Stopa N, Krebs JE, Shechter D. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cell Mol Life Sci. 2015;72:2041\u201359.","journal-title":"Cell Mol Life Sci"},{"key":"1558_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1417502","author":"X Sun","year":"2024","unstructured":"Sun X, et al. Post-translational modifications of p65: state of the art. Front Cell Dev Biol. 2024. https:\/\/doi.org\/10.3389\/fcell.2024.1417502.","journal-title":"Front Cell Dev Biol"},{"key":"1558_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41419-019-2212-y","volume":"11","author":"S Thatikonda","year":"2020","unstructured":"Thatikonda S, Pooladanda V, Sigalapalli DK, Godugu C. Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation. Cell Death Dis. 2020;11:21.","journal-title":"Cell Death Dis"},{"key":"1558_CR34","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1002\/jcb.27936","volume":"120","author":"Y Wang","year":"2019","unstructured":"Wang Y, Huo J, Zhang D, Hu G, Zhang Y. Chemerin\/ChemR23 axis triggers an inflammatory response in keratinocytes through ROS-sirt1-NF-\u03baB signaling. J Cell Biochem. 2019;120:6459\u201370.","journal-title":"J Cell Biochem"},{"key":"1558_CR35","doi-asserted-by":"publisher","first-page":"13516","DOI":"10.1073\/pnas.1311784110","volume":"110","author":"H Wei","year":"2013","unstructured":"Wei H, et al. PRMT5 dimethylates R30 of the p65 subunit to activate NF-\u03baB. Proc Natl Acad Sci U S A. 2013;110:13516\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1558_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/bjd.19057","volume":"184","author":"L Yang","year":"2021","unstructured":"Yang L, et al. Upregulated E3 ligase tripartite motif-containing protein 21 in psoriatic epidermis ubiquitylates nuclear factor-\u03baB p65 subunit and promotes inflammation in keratinocytes*. Br J Dermatol. 2021;184:111\u201322.","journal-title":"Br J Dermatol"},{"key":"1558_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrc3409","volume":"13","author":"Y Yang","year":"2013","unstructured":"Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2013;13:37\u201350.","journal-title":"Nat Rev Cancer"},{"key":"1558_CR38","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/nsmb.1568","volume":"16","author":"Q Zhao","year":"2009","unstructured":"Zhao Q, et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol. 2009;16:304\u201311.","journal-title":"Nat Struct Mol Biol"},{"key":"1558_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13:81.","journal-title":"Cell Death Dis"},{"key":"1558_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17856","volume":"28","author":"H Zhou","year":"2023","unstructured":"Zhou H, et al. PRMT5 activates KLF5 by methylation to facilitate lung cancer. J Cell Mol Med. 2023;28:e17856.","journal-title":"J Cell Mol Med"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01558-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:47:29Z","timestamp":1791157649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01558-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01558-6","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were performed in accordance with institutional guidelines and approved by the Animal Ethics Committee of Xiangya Hospital, Central South University (Approval No. 202310046). The use of human psoriasis tissue sections was approved by the Ethics Committee of Xiangya Hospital, Central South University (Approval No. 2024070866).This study used anonymized archived human psoriasis tissue sections. The use of human tissue specimens was approved by the Ethics Committee of Xiangya Hospital, Central South University (Approval No. 2024070866). Individual informed consent was waived by the Ethics Committee given the retrospective and anonymized nature of the samples.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the manuscript and agreed to its publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"172"}}